Fang, Zhenhao
Monteiro, Valter S. http://orcid.org/0000-0003-1785-6713
Hahn, Anne M. http://orcid.org/0000-0003-0710-6775
Grubaugh, Nathan D.
Lucas, Carolina
Chen, Sidi http://orcid.org/0000-0002-3819-5005
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0019)
Article History
Received: 14 July 2022
Accepted: 17 September 2022
First Online: 11 October 2022
Conflict of interest
: We declare that none of the authors has competing financial or non-financial interests related to this study as defined by Nature Portfolio. S.C. is a Founder of EvolveImmune Tx, Cellinfinity Bio, and Chen Consulting, all unrelated to this study. N.G. is a paid consultant for Tempus Labs and the National Basketball Association, and has received speaking fees from Moderna. The remaining authors declare no competing interest.
: The Yale Human Research Protection Program Institutional Review Board determined that the sequencing and generating a SARS-CoV-2 isolate from de-identified remnant COVID-19 clinical samples in this study were not research involving human participants (IRB protocol ID 2000028599).